Centauri Therapeutics raises £6M from AMR Action Fund, extending its Series A round to £30M. The funding will aid Phase I clinical studies for its lead candidate CTX-187.
PRIVATEFeb 24, 2026
Amount Raised
£6 Million
Round Type
Series A
LondonOtherBiotechnologyHealth CareTherapeutics
Investors
AMR Action Fund
Description
Centauri Therapeutics Limited has secured £6M from AMR Action Fund, extending its Series A round to £30M. The investment supports the advancement of its lead clinical candidate, CTX-187, through Phase I trials. Additionally, it will enable further research preparations for Phase II studies. Dr
Who to call at Centaurus Therapeutics, and when
A new round usually means Centaurus Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Centaurus Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Centaurus Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Centaurus Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Centaurus Therapeutics
Location
London, England, United Kingdom
About
Centauri Therapeutics Limited is a UK-based biotechnology company developing novel treatments for life-threatening diseases using its proprietary Alphamer technology. This approach harnesses "programmable immunity" by redirecting natural antibodies to target pathogens, using molecules that bind to pathogens and present epitopes to trigger an immune response. Backed by strong IP and a portfolio of patents, Centauri is advancing specific leads with the potential to deliver fast, targeted antibacterial therapies.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Centaurus Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.